Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $33.00.

Several analysts have recently weighed in on the company. Piper Sandler assumed coverage on Avalo Therapeutics in a research report on Friday, February 28th. They set an “overweight” rating and a $48.00 target price for the company. Stifel Nicolaus assumed coverage on shares of Avalo Therapeutics in a report on Tuesday. They set a “buy” rating and a $36.00 price objective for the company. BTIG Research started coverage on shares of Avalo Therapeutics in a research report on Thursday, December 19th. They issued a “buy” rating and a $40.00 price objective for the company. HC Wainwright reaffirmed a “neutral” rating on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Finally, Jefferies Financial Group initiated coverage on Avalo Therapeutics in a report on Tuesday. They issued a “buy” rating and a $23.00 price target for the company.

Avalo Therapeutics Price Performance

Shares of AVTX stock traded up $1.16 on Tuesday, reaching $8.79. 121,259 shares of the company’s stock were exchanged, compared to its average volume of 210,375. The company’s fifty day simple moving average is $7.47 and its 200 day simple moving average is $9.13. Avalo Therapeutics has a 52 week low of $4.60 and a 52 week high of $34.46.

Institutional Investors Weigh In On Avalo Therapeutics

Large investors have recently modified their holdings of the business. Tower Research Capital LLC TRC boosted its stake in shares of Avalo Therapeutics by 998.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock valued at $31,000 after purchasing an additional 3,754 shares in the last quarter. Marshall Wace LLP purchased a new stake in Avalo Therapeutics during the fourth quarter worth $114,000. Walleye Capital LLC bought a new stake in Avalo Therapeutics during the 4th quarter valued at $145,000. Northern Trust Corp purchased a new position in shares of Avalo Therapeutics in the 4th quarter valued at $168,000. Finally, Bank of Montreal Can purchased a new position in shares of Avalo Therapeutics in the 4th quarter valued at $446,000. Institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.